Clinical trials
Relapsed/Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed/refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 102 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05730036RecruitingPhase 3
Linvoseltamab vs standard treatment for relapsed myeloma
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT05759793RecruitingPhase 1
CAR T trial for relapsed myeloma targeting GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
ShanghaiAges 18–75 - NCT05862012RecruitingPhase 1
Test drug ISB 2001 in multiple myeloma patients who relapsed
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
Palo Alto, CaliforniaAges 18 years+ - NCT05896228RecruitingPhase 2
Combination therapy for relapsed multiple myeloma to target MRD
This Phase 2 trial tests iberdomide plus daratumumab, carfilzomib, and dexamethasone in people whose multiple myeloma has come back or not responded. The goal is to increase how often patients reach “MRD-negative” status, meaning very small amounts of cancer cells are not detectable, which may help improve outcomes.
Miami, FloridaAges 18–75 - NCT05922501RecruitingPhase 2
Test four medicines for relapsed multiple myeloma
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
Boston, MassachusettsAges 18 years+ - NCT05998928RecruitingPhase 2
BCMA-GPRC5D CAR-T for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
Wuhan, HubeiAges 18–75 - NCT06049290RecruitingPhase 1/Phase 2
Study of LBL-034 for relapsed or refractory multiple myeloma
This trial tests a new drug called LBL-034 in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if it is safe and effective.
Wuhu, AnhuiAges 18 years+ - NCT06105554RecruitingPhase 1/Phase 2
Study of belumosudil for relapsed or refractory multiple myeloma
This trial tests a new drug called belumosudil, alone or with dexamethasone, for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if it can help when other therapies have stopped working.
Houston, TexasAges 18 years+ - NCT06115135RecruitingPhase 2
Venetoclax with isatuximab and dexamethasone for myeloma
This trial tests a combination of three drugs (venetoclax, isatuximab, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to earlier treatments. It is for patients whose cancer cells have a specific genetic change, called t(11;14).
West Hollywood, CaliforniaAges Any age - NCT06158841RecruitingPhase 3
Etentamig vs standard therapy for relapsed myeloma
This trial tests a new IV treatment called etentamig compared to standard therapies for people with multiple myeloma that has come back or stopped responding. It may be an option if you've already tried at least two different treatments, including common drug classes.
Birmingham, AlabamaAges 18 years+ - NCT06232096RecruitingPhase 1/Phase 2
Study of MBS314 for relapsed or refractory multiple myeloma
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
BeijingAges 18 years+ - NCT06235229RecruitingPhase 1/Phase 2
GC012F for relapsed/refractory multiple myeloma
This trial tests a new CAR-T cell therapy called GC012F for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this treatment can help control the disease.
BeijingAges 18–75 - NCT06270888RecruitingPhase 1
Shorter radiation treatment for multiple myeloma
This trial tests a shorter course of radiation therapy for up to 5 bone lesions that have come back or not responded to treatment. It aims to see if this approach is safe and helps control the disease.
Chicago, IllinoisAges 18 years+ - NCT06279026Recruiting
Testing UTAA17 for advanced multiple myeloma
This trial tests a new treatment called UTAA17 that targets a protein on myeloma cells. It may be an option for people whose multiple myeloma has not responded to several prior treatments.
Suzhou, JiangsuAges 18 years+ - NCT07454187RecruitingPhase 1/Phase 2
SG2918 for relapsed or refractory multiple myeloma
This trial tests a new drug called SG2918 for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and possibly effective.
Zhengzhou, HenanAges 18–80 - NCT06421675RecruitingPhase 2
Elranatamab for multiple myeloma that has come back
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
Vancouver, British ColumbiaAges 18 years+ - NCT06485076Recruiting
Early comfort care for multiple myeloma and aggressive lymphoma
This study offers a palliative care team (doctors and nurses focused on comfort and quality of life) to people newly diagnosed with multiple myeloma or with an aggressive lymphoma that has come back. The goal is to help manage symptoms early, so you feel better and stay stronger during your cancer treatment.
Toronto, OntarioAges 18 years+ - NCT06508983RecruitingPhase 3
SG301 for multiple myeloma returning after treatment
This trial tests a new drug called SG301 added to standard treatments (pomalidomide and dexamethasone) for people with multiple myeloma that came back or got worse after prior therapy. It may help if you have tried lenalidomide and a proteasome inhibitor but your cancer is still active.
Beijing, Beijing MunicipalityAges 18–75 - NCT06561854RecruitingPhase 3
Comparing multiple myeloma treatment with and without dexamethasone
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
ParisAges 18 years+ - NCT06581640RecruitingPhase 2
BCMA-targeting CAR-T cells for relapsed/refractory myeloma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
Xiamen, FujianAges 18–80 - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT06668792RecruitingPhase 2
Study of BCD-248 for returning multiple myeloma
This trial tests a new treatment called BCD-248 for people whose multiple myeloma has come back or stopped responding to at least two prior treatments. It aims to see if it is safe and effective.
KaliningradAges 18 years+ - NCT05160584Recruiting
Real-world treatment study for relapsed or refractory myeloma
This study follows people with multiple myeloma that has come back or stopped responding to treatment, and looks at how current care is used in real life. It may include people starting talquetamab, and aims to understand outcomes and treatment patterns outside of strict experimental settings.
LeobenAges 18 years+ - NCT06711705RecruitingPhase 2
Elranatamab for relapsed or refractory multiple myeloma
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
La Jolla, CaliforniaAges 18 years+
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed/refractory multiple myeloma?
- Yes. Clin2 currently lists 102 recruiting relapsed/refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed/refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed/refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.